Senti Biosciences, Inc. (SNTI) fell 23.88 percent to $3.80, down $1.19 during Monday's trading, even after the company reported additional positive preliminary data from its Phase 1 trial of SENTI-202, an off-the-shelf CAR-NK cell therapy candidate for relapsed/refractory hematologic malignancies including AML.
The stock opened at $4.7600 and traded between $3.8100 and $4.9500 during the session on the Nasdaq. Volume reached 3.37 million shares, significantly higher than the average daily volume of 30,470. Senti Biosciences' 52-week range is $1.5200 to $16.9400.
The company plans to discuss the new data in a conference call and webcast scheduled for today.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.